Trial Profile
To Assess the Efficacy and Safety of Ramosetron, Aprepitant and Dexamethasone Therapy vs Ondansetron, Aprepitant and Dexamethasone Therapy for Preventing of Nausea and Vomiting in Highly Emetogenic Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Ramosetron (Primary) ; Aprepitant; Dexamethasone; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Acronyms ROAD
- 18 Jun 2013 Status changed from recruiting to completed.
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2013 Primary endpoint 'Complete-clinical-response' has been met.